By Matthew Bultman ( March 6, 2017, 5:05 PM EST) -- Celltrion Inc. lost a renewed effort to challenge in inter partes review a Genentech Inc. patent on a method of treating rheumatoid arthritis, as the Patent Trial and Appeal Board decided it hadn't shown any of the patent's claims were likely invalid....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.